279 related articles for article (PubMed ID: 24116915)
1. Novel therapy based on camelid nanobodies.
Unciti-Broceta JD; Del Castillo T; Soriano M; Magez S; Garcia-Salcedo JA
Ther Deliv; 2013 Oct; 4(10):1321-36. PubMed ID: 24116915
[TBL] [Abstract][Full Text] [Related]
2. Camelid single-domain antibody fragments: Uses and prospects to investigate protein misfolding and aggregation, and to treat diseases associated with these phenomena.
Pain C; Dumont J; Dumoulin M
Biochimie; 2015 Apr; 111():82-106. PubMed ID: 25656912
[TBL] [Abstract][Full Text] [Related]
3. Camelid nanobodies: killing two birds with one stone.
Desmyter A; Spinelli S; Roussel A; Cambillau C
Curr Opin Struct Biol; 2015 Jun; 32():1-8. PubMed ID: 25614146
[TBL] [Abstract][Full Text] [Related]
4. Introduction to heavy chain antibodies and derived Nanobodies.
Vincke C; Muyldermans S
Methods Mol Biol; 2012; 911():15-26. PubMed ID: 22886243
[TBL] [Abstract][Full Text] [Related]
5. Camelid immunoglobulins and nanobody technology.
Muyldermans S; Baral TN; Retamozzo VC; De Baetselier P; De Genst E; Kinne J; Leonhardt H; Magez S; Nguyen VK; Revets H; Rothbauer U; Stijlemans B; Tillib S; Wernery U; Wyns L; Hassanzadeh-Ghassabeh G; Saerens D
Vet Immunol Immunopathol; 2009 Mar; 128(1-3):178-83. PubMed ID: 19026455
[TBL] [Abstract][Full Text] [Related]
6. Nanobodies: natural single-domain antibodies.
Muyldermans S
Annu Rev Biochem; 2013; 82():775-97. PubMed ID: 23495938
[TBL] [Abstract][Full Text] [Related]
7. Generation of single domain antibody fragments derived from camelids and generation of manifold constructs.
Vincke C; Gutiérrez C; Wernery U; Devoogdt N; Hassanzadeh-Ghassabeh G; Muyldermans S
Methods Mol Biol; 2012; 907():145-76. PubMed ID: 22907350
[TBL] [Abstract][Full Text] [Related]
8. Nanobodies and their potential applications.
Hassanzadeh-Ghassabeh G; Devoogdt N; De Pauw P; Vincke C; Muyldermans S
Nanomedicine (Lond); 2013 Jun; 8(6):1013-26. PubMed ID: 23730699
[TBL] [Abstract][Full Text] [Related]
9. Camelid Single-Domain Antibodies for the Development of Potent Diagnosis Platforms.
Brilhante-da-Silva N; de Oliveira Sousa RM; Arruda A; Dos Santos EL; Marinho ACM; Stabeli RG; Fernandes CFC; Pereira SDS
Mol Diagn Ther; 2021 Jul; 25(4):439-456. PubMed ID: 34146333
[TBL] [Abstract][Full Text] [Related]
10. Small nanobody drugs win big backing from pharma.
Williams SC
Nat Med; 2013 Nov; 19(11):1355-6. PubMed ID: 24202374
[No Abstract] [Full Text] [Related]
11. Identification of Useful Nanobodies by Phage Display of Immune Single Domain Libraries Derived from Camelid Heavy Chain Antibodies.
Romao E; Morales-Yanez F; Hu Y; Crauwels M; De Pauw P; Hassanzadeh GG; Devoogdt N; Ackaert C; Vincke C; Muyldermans S
Curr Pharm Des; 2016; 22(43):6500-6518. PubMed ID: 27669966
[TBL] [Abstract][Full Text] [Related]
12. Site-specific labeling of cysteine-tagged camelid single-domain antibody-fragments for use in molecular imaging.
Massa S; Xavier C; De Vos J; Caveliers V; Lahoutte T; Muyldermans S; Devoogdt N
Bioconjug Chem; 2014 May; 25(5):979-88. PubMed ID: 24815083
[TBL] [Abstract][Full Text] [Related]
13. Single domain antibodies from camelids in the treatment of microbial infections.
De Greve H; Fioravanti A
Front Immunol; 2024; 15():1334829. PubMed ID: 38827746
[TBL] [Abstract][Full Text] [Related]
14. A novel promiscuous class of camelid single-domain antibody contributes to the antigen-binding repertoire.
Deschacht N; De Groeve K; Vincke C; Raes G; De Baetselier P; Muyldermans S
J Immunol; 2010 May; 184(10):5696-704. PubMed ID: 20404276
[TBL] [Abstract][Full Text] [Related]
15. [Advances in the study of natural small molecular antibody].
Zhu L; Zhang DP
Yao Xue Xue Bao; 2012 Oct; 47(10):1281-6. PubMed ID: 23289139
[TBL] [Abstract][Full Text] [Related]
16. Generation, expression and utilization of single-domain antibodies for in vivo protein localization and manipulation in sea urchin embryos.
Schrankel CS; Gökirmak T; Lee CW; Chang G; Hamdoun A
Methods Cell Biol; 2019; 151():353-376. PubMed ID: 30948018
[TBL] [Abstract][Full Text] [Related]
17. The development of nanobodies for therapeutic applications.
Van Bockstaele F; Holz JB; Revets H
Curr Opin Investig Drugs; 2009 Nov; 10(11):1212-24. PubMed ID: 19876789
[TBL] [Abstract][Full Text] [Related]
18. A camelid antibody candidate for development of a therapeutic agent against Hemiscorpius lepturus envenomation.
Yardehnavi N; Behdani M; Bagheri KP; Mahmoodzadeh A; Khanahmad H; Shahbazzadeh D; Habibi-Anbouhi M; Hassanzadeh Ghassabeh G; Muyldermans S
FASEB J; 2014 Sep; 28(9):4004-14. PubMed ID: 24891523
[TBL] [Abstract][Full Text] [Related]
19. Antibody repertoire development in camelids.
De Genst E; Saerens D; Muyldermans S; Conrath K
Dev Comp Immunol; 2006; 30(1-2):187-98. PubMed ID: 16051357
[TBL] [Abstract][Full Text] [Related]
20. Immunotoxins and nanobody-based immunotoxins: review and update.
Khirehgesh MR; Sharifi J; Safari F; Akbari B
J Drug Target; 2021 Sep; 29(8):848-862. PubMed ID: 33615933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
